Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Natasha on +44 1494 818 053 or natasha@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Natasha Wilson
Executive Recruiter
natasha@zenopa.com
+44 1494 818 053

Testimonials
I want to thank Zenopa for their time and efforts in helping me during my job search, you have given me the extra confidence I need to keep me pro-active in my search.
Mohammed, 2011

Forest Laboratories reports positive data on depression treatment

7 March 2012 00:00 in Pharmaceutical Company Product News


Forest Laboratories has announced positive new clinical trial data supporting the efficacy of its drug levomilnacipran against major depressive disorder (MDD).

Developed in association with Pierre Fabre Medicament, the investigational agent was shown to significantly reduce depression symptoms in patients with MDD compared to placebo, delivering benefits within a week.

The new study represents the second phase III trial to demonstrate a positive outcome for levomilnacipran among this patient population, with further data analyses currently ongoing.

Dr Marco Taglietti, senior vice-president for research and development and president of the Forest Research Institute, said: "We have successfully completed two positive phase III studies for the treatment of MDD in adults and plan to file a new drug application for levomilnacipran with the Food and Drug Administration later this year."

Last month, Forest Laboratories expanded its UK product offering with the launch of Colobreathe, a new inhaler-based treatment for chronic lung infections among cystic fibrosis patients.ADNFCR-8000103-ID-801311508-ADNFCR

Other news stories from 07/03/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2015 Zenopa Ltd